phenylalanine has been researched along with imatinib mesylate in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brasher, BB; Gorre, ME; Nicoll, J; Roumiantsev, S; Sawyers, CL; Shah, NP; Van Etten, RA | 1 |
| Hervé, F; Marie, I | 1 |
| Bay, JO; Berger, MG; Chaleteix, C; Fleury, J; Gouas, L; Goumy, C; Ledoux-Pilon, A; Richard-Pebrel, C; Tchirkov, A; Tournilhac, O; Vago, P; Véronèse, L | 1 |
| Bassan, R; Bussini, A; Castagnetti, F; Gnani, A; Intermesoli, T; Rosti, G; Soverini, S; Spinelli, O | 1 |
1 review(s) available for phenylalanine and imatinib mesylate
| Article | Year |
|---|---|
[Mutation of protein kinase JAK2 in polycythemia vera: new perspectives in physiopathology and therapy].
Topics: Amino Acid Substitution; Benzamides; Chromosomes, Human, Pair 9; Humans; Imatinib Mesylate; Janus Kinase 2; Phenylalanine; Piperazines; Point Mutation; Polycythemia Vera; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Valine | 2006 |
3 other study(ies) available for phenylalanine and imatinib mesylate
| Article | Year |
|---|---|
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenylalanine; Phosphorylation; Piperazines; Point Mutation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Tyrosine | 2002 |
A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.
Topics: Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloproliferative Disorders; Phenylalanine; Piperazines; Pyrimidines; Thrombocytosis; Valine | 2010 |
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.
Topics: Adult; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Dasatinib; Female; Fusion Proteins, bcr-abl; Glutamic Acid; Humans; Imatinib Mesylate; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysine; Mutation, Missense; Phenylalanine; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Remission Induction; Thiazoles; Time Factors; Treatment Outcome | 2012 |